Last reviewed · How we verify

NCT03687021

Clinical Study on Endometrial Receptivity

Status unknown EARLY_PHASE1 Last updated 27 September 2018
What this trial tests

EARLY_PHASE1 trial testing Progesterone in Endometrial Receptivity;RNA; Progesterone in 35 participants. Status unknown.

Timeline
10 October 2018
Primary endpoint
10 October 2018
10 November 2018

Quick facts

Lead sponsorPeking Union Medical College Hospital
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposediagnostic
Enrollment35
Start date10 October 2018
Primary completion10 October 2018
Estimated completion10 November 2018
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 40, female only, with Endometrial Receptivity;RNA; Progesterone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

to explore the differential expression of miRNA in the implantation window of patients with endometriosis and the time of progesterone and route of administration on planting window

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Progesterone

Trials testing the same drug.

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03687021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing